USANA Health Sciences Inc. (USNA) PT Raised to $105 at Pivotal Research

Pivotal Research analyst Timothy Ramey raised the price target on USANA Health Sciences Inc. (NYSE: USNA) to $105.00 (from $95.00) while maintaining a Buy rating.

Ramey commented, "USNA’s 1Q19 EPS at $1.01 vs. was in line with the pre-release range and our $1.00 estimate. As previously announced, the company was negatively impacted by the “100-day review of heath products” which the Chinese government launched in the 2nd week of January. This review put a clamp on large company meetings for all three MLMs we follow, and the expectation of that impact was more severe for USNA, which derived 52.8% of sales from Greater China, and the majority of those are nutritional products. The company cited a back-half weighted promotional calendar as another reason for 1Q weakness and management allowed that this was a mistake in hindsight."

You May Also Be Interested In

• Take-Two Interactive (TTWO) PT Raised to $368 at BofA Securities
• Cytokinetics (CYTK) PT Raised to $118 at Mizuho
• Ralliant Corp. (RAL) PT Raised to $85 at Morgan Stanley: 'organic pathway to sustained HSD into 2027'